journal
MENU ▼
Read by QxMD icon Read
search

Translational Lung Cancer Research

journal
https://www.readbyqxmd.com/read/29876321/considerations-when-treating-lung-cancer-with-passive-scatter-or-active-scanning-proton-therapy
#1
REVIEW
Sara St James, Clemens Grassberger, Hsiao-Ming Lu
Lung cancer, due to its poor clinical outcomes and significant toxicity associated with standard photon-based radiation, is a disease site that has the potential to greatly benefit from accurate treatment with proton radiation therapy. The potential of proton therapy is the ability to increase the radiation dose to the tumor while simultaneously decreasing the radiation dose to surrounding healthy tissues. For lung cancer treatment, this could mean significant sparing of the uninvolved healthy lung, which is difficult to achieve with external photon beam therapy, or decreasing the heart dose...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876320/proton-therapy-for-post-operative-radiation-therapy-of-non-small-cell-lung-cancer
#2
REVIEW
Annemarie Fernandes Shepherd
Post-operative radiation therapy (PORT) is typically recommended for patients with locally advanced non-small cell lung cancer (NSCLC) with N2 mediastinal nodal involvement after surgical resection. The routine use of PORT, however, is controversial as older data demonstrated a detriment in overall survival in patients who received PORT. This detriment was thought to be due to older, more toxic radiation techniques. More recent data with modern radiation techniques demonstrates a local-regional and overall survival benefit with PORT in patients with N2 nodal involvement...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876319/proton-therapy-for-early-stage-non-small-cell-lung-cancer-nsclc
#3
REVIEW
Daniel R Gomez, Heng Li, Joe Y Chang
In the setting of early-stage non-small cell lung cancer (NSCLC), defining the optimal clinical context for proton beam therapy (PBT) is challenging due to the increasing evidence demonstrating high rates of local control and good tolerance of stereotactic ablative body radiation (SABR). Given the relatively small percentage of lung and other critical structures treated with SABR, dosimetric studies comparing the two techniques have typically concluded that there are modest advantages to PBT, typically by reducing the low dose volumes, such as volume of lung receiving 5 Gy...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876318/proton-beam-therapy-for-malignant-pleural-mesothelioma
#4
REVIEW
Shahed N Badiyan, Jason K Molitoris, Mingyao Zhu, Erica Glass, Tejan Diwanji, Charles B Simone
Malignant pleural mesothelioma (MPM) is a rare disease with a poor prognosis. Surgical techniques have made incremental improvements over the last few decades while new systemic therapies, including immunotherapies, show promise as potentially effective novel therapies. Radiation therapy has historically been used only in the palliative setting or as adjuvant therapy after extrapleural pneumonectomy, but recent advances in treatment planning and delivery techniques utilizing intensity-modulated radiation therapy and more recently pencil-beam scanning (PBS) proton therapy, have enabled the delivery of radiation therapy as neoadjuvant or adjuvant therapy after an extended pleurectomy and decortication or as definitive therapy for patients with recurrent or unresectable disease...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876317/proton-beam-therapy-and-immunotherapy-an-emerging-partnership-for-immune-activation-in-non-small-cell-lung-cancer
#5
REVIEW
Howard J Lee, Jing Zeng, Ramesh Rengan
Proton beam therapy (PBT) is becoming an increasingly common option for patients undergoing radiation therapy (RT). With the concurrent emergence of immunotherapy as an effective systemic treatment for historically treatment-resistant disease such as advanced non-small cell lung cancer (NSCLC), the combination of RT's immunoadjuvant effects with immunotherapy is gaining widespread attention. However, pre-clinical and clinical studies have shown potential immunosuppressive mechanisms associated with conventional RT that may restrict its immunogenic potential...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876316/advanced-proton-beam-dosimetry-part-i-review-and-performance-evaluation-of-dose-calculation-algorithms
#6
REVIEW
Jatinder Saini, Erik Traneus, Dominic Maes, Rajesh Regmi, Stephen R Bowen, Charles Bloch, Tony Wong
The accuracy of dose calculation is vital to the quality of care for patients undergoing proton beam therapy (PBT). Currently, the dose calculation algorithms available in commercial treatment planning systems (TPS) in PBT are classified into two classes: pencil beam (PB) and Monte-Carlo (MC) algorithms. PB algorithms are still regarded as the standard of practice in PBT, but they are analytical approximations whereas MC algorithms use random sampling of interaction cross-sections that represent the underlying physics to simulate individual particles trajectories...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876315/image-guidance-in-proton-therapy-for-lung-cancer
#7
REVIEW
Miao Zhang, Wei Zou, Boon-Keng Kevin Teo
Proton therapy is a promising but challenging treatment modality for the management of lung cancer. The technical challenges are due to respiratory motion, low dose tolerance of adjacent normal tissue and tissue density heterogeneity. Different imaging modalities are applied at various steps of lung proton therapy to provide information on target definition, target motion, proton range, patient setup and treatment outcome assessment. Imaging data is used to guide treatment design, treatment delivery, and treatment adaptation to ensure the treatment goal is achieved...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876314/proton-therapy-for-thoracic-reirradiation-of-non-small-cell-lung-cancer
#8
REVIEW
Hann-Hsiang Chao, Abigail T Berman
Lung cancer is a leading cause of cancer death with frequent local failures after initial curative-intent treatment. Locally recurrent non-small cell lung cancer represents a challenging clinical scenario as patients have often received prior radiation as part of a definitive treatment regimen. Proton beam therapy, through its characteristic Bragg peak and lack of exit dose is a potential means of minimizing the toxicity to previously irradiated organs and improving the therapeutic ratio. This article aims to review the rationale for the use of proton beam therapy for treatment of locally recurrent non-small cell lung cancer, highlight the current published experience on the feasibility, efficacy, and limitations of proton beam reirradiation, and discuss future avenues for improved patient selection and treatment delivery...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876313/particle-therapy-in-non-small-cell-lung-cancer
#9
REVIEW
Zhongxing Liao, Charles B Simone
The finite range of proton beams in tissues offers unique dosimetric advantages that theoretically allow the dose to the target to be escalated while minimizing exposure of surrounding tissues and thereby minimizing radiation-induced toxicity. These theoretical advantages have led to widespread adoption of proton therapy around the world for a wide variety of tumors at different anatomic sites. Many treatment-planning comparisons have shown that proton therapy has substantial dosimetric advantages over conventional photon (X-ray) radiation therapy...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876312/proton-therapy-for-small-cell-lung-cancer
#10
REVIEW
Vivek Verma, J Isabelle Choi, Charles B Simone
The prognosis of limited-stage small cell lung cancer (LS-SCLC) continues to improve and is now roughly comparable to that of locally advanced non-small cell lung cancer (NSCLC). This shift, taken together with the decreased toxicities of modern radiotherapy (RT) for LS-SCLC compared with those reported in historical trials, necessitates further evaluation of whether proton beam therapy (PBT) could further reduce both acute and late toxicities for patients receiving concurrent chemoradiotherapy for LS-SCLC...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876311/decision-analytic-modeling-for-the-economic-analysis-of-proton-radiotherapy-for-non-small-cell-lung-cancer
#11
Wade P Smith, Patrick J Richard, Jing Zeng, Smith Apisarnthanarax, Ramesh Rengan, Mark H Phillips
Background: Although proton radiation treatments are more costly than photon/X-ray therapy, they may lower overall treatment costs through reducing rates of severe toxicities and the costly management of those toxicities. To study this issue, we created a decision-model comparing proton vs. X-ray radiotherapy for locally advanced non-small cell lung cancer patients. Methods: An influence diagram was created to model for radiation delivery, associated 6-month pneumonitis/esophagitis rates, and overall costs (radiation plus toxicity costs)...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876310/advanced-proton-beam-dosimetry-part-ii-monte-carlo-vs-pencil-beam-based-planning-for-lung-cancer
#12
Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R Bowen
Background: Proton pencil beam (PB) dose calculation algorithms have limited accuracy within heterogeneous tissues of lung cancer patients, which may be addressed by modern commercial Monte Carlo (MC) algorithms. We investigated clinical pencil beam scanning (PBS) dose differences between PB and MC-based treatment planning for lung cancer patients. Methods: With IRB approval, a comparative dosimetric analysis between RayStation MC and PB dose engines was performed on ten patient plans...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876309/rationale-and-early-outcomes-for-the-management-of-thymoma-with-proton-therapy
#13
He J Zhu, Bradford S Hoppe, Stella Flampouri, Debbie Louis, John Pirris, R Charles Nichols, Randal H Henderson, Catherine E Mercado
Background: Radiotherapy for thymic malignancies is technically challenging due to their close proximity to the heart, lungs, esophagus, and breasts, raising concerns about significant acute and late toxicities from conventional photon radiotherapy. Proton therapy (PT) may reduce the radiation dose to these vital organs, leading to less toxicity. We reviewed the dosimetry and outcomes among patients treated with PT for thymic malignancies at our institution. Methods: From January 2008 to March 2017, six patients with de novo Masaoka stages II-III thymic malignancies were treated with PT on an IRB-approved outcomes tracking protocol...
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29876308/proton-therapy-in-non-small-cell-lung-cancer
#14
Ramesh Rengan, Jing Zeng
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29782572/patient-related-outcomes-with-the-use-of-checkpoint-inhibitors-for-the-treatment-of-metastatic-non-small-cell-lung-cancer
#15
EDITORIAL
Jyoti Malhotra, Salma K Jabbour
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29782570/egfr-targeted-therapy-for-lung-cancer-are-we-almost-there
#16
EDITORIAL
Giulio Metro
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29782569/patient-selection-for-future-lung-cancer-computed-tomography-screening-programmes-lessons-learnt-post-national-lung-cancer-screening-trial
#17
EDITORIAL
John K Field, Stephen W Duffy, David R Baldwin
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29782567/quality-of-life-for-non-small-cell-lung-cancer-patients-in-the-age-of-immunotherapy
#18
EDITORIAL
Robert A Ramirez, Jonathan Lu, Katharine E H Thomas
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29782566/post-operative-radiation-therapy-in-locally-advanced-non-small-cell-lung-cancer-and-the-impact-of-sequential-versus-concurrent-chemotherapy
#19
EDITORIAL
Mark R Waddle, Stephen Ko, Margaret M Johnson, Yanyan Lou, Robert C Miller, Anna C Harrell, Daniel M Trifiletti
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29782565/nivolumab-in-pretreated-non-small-cell-lung-cancer-continuing-the-immunolution
#20
EDITORIAL
Massimiliano Salati, Cinzia Baldessari, Bruna Cerbelli, Andrea Botticelli
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
journal
journal
49936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"